India, July 29 -- Dyne Therapeutics Inc. (DYN), a clinical-stage company developing treatments for genetically driven neuromuscular diseases, is advancing its programs in Myotonic Dystrophy and Duchenne Muscular Dystrophy, aiming for potential commercial launches by 2027.
Myotonic dystrophy type 1 (DM1), also known as a triplet repeat disease, is caused due to a defective DMPK gene. The DMPK gene provides instructions for making a protein called myotonic dystrophy protein kinase, which plays an important role in the development of muscle, heart, and brain cells. Muscle weakness throughout the body, Myotonia, or difficulty relaxing muscles in the jaw, tongue, throat, lower arm, and hand, Respiratory issues, and Cognitive deficits are some o...